Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Chronic hepatitis treated with alpha-interferon].

M Michael1

  • 1Institut f. Angewandte u. Experimentelle Onkologie, Universität Wien, Austria.

Orvosi Hetilap
|July 5, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CIDP With and Without Monoclonal Gammopathy of Undetermined Significance (MGUS): Comparison of Clinical Phenotype, Diagnostic Features, and Treatment Response.

Journal of the peripheral nervous system : JPNS·2026
Same author

Impact of neoadjuvant FOLFIRINOX over upfront resection in borderline resectable pancreatic cancer-an international, multicentre, real-world analysis.

ESMO real world data and digital oncology·2026
Same author

Integrating behavioral assessment in instructional design for competency-based medical education.

Frontiers in medicine·2024
Same author

Incidence, prevalence, and survival trends for neuroendocrine neoplasms in Victoria, Australia, from 1982 to 2019: Based on site, grade, and region.

Asia-Pacific journal of clinical oncology·2021
Same author

An Experimental Study on the Rheological Behavior of Carbon Black-Boron Nitride Hybrid Nanofluids and Development of a New Correlation.

Journal of nanoscience and nanotechnology·2021
Same author

Immune Checkpoint Blockade in Lower Gastrointestinal Cancers: A Systematic Review.

Annals of surgical oncology·2021
Same journal

[The application of artificial intelligence in healthcare: benefits, challenges, and issues of responsibility].

Orvosi hetilap·2026
Same journal

[Long-COVID syndrome and lung-specific abnormalities following COVID-19].

Orvosi hetilap·2026
Same journal

[Validation of the Vaccination Attitudes Examination (VAX) scale in Hungary].

Orvosi hetilap·2026
Same journal

Orvosi hetilap·2026
Same journal

[The Hungarian short version and psychometric properties of the Activities-specific Balance Confidence Scale for assessing fall risk].

Orvosi hetilap·2026
Same journal

[Hungarian primary care: facts, problems and expectations].

Orvosi hetilap·2026
See all related articles

Interferon therapy shows promise for chronic viral hepatitis, with higher response rates in type C than type B. However, relapses are common in type C, and optimal treatment duration remains unclear.

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Chronic viral hepatitis, including types B and C, poses a significant global health challenge.
  • Interferon therapy has been a cornerstone in managing chronic viral hepatitis.
  • Controlled trials provide crucial data on treatment efficacy and patient outcomes.

Purpose of the Study:

  • To report the latest findings on interferon treatment for chronic viral hepatitis.
  • To evaluate the response rates and identify challenges associated with interferon therapy.
  • To highlight areas requiring further research, such as treatment duration and specific viral types.

Main Methods:

  • Systematic review of controlled clinical trials on interferon treatment for chronic viral hepatitis.
  • Analysis of patient response rates based on hepatitis viral type (B, C, and Delta).

Related Experiment Videos

  • Assessment of treatment efficacy, relapse rates, and identification of unresolved therapeutic questions.

    • Main Results:

    • Interferon treatment demonstrated a good response in approximately 35% of chronic type B hepatitis patients.
    • A significant good response was observed in 80% of chronic type C hepatitis patients.
    • Frequent relapses were noted in chronic type C hepatitis patients after cessation of interferon treatment.
    • Further therapeutic studies are needed for hepatitis Delta infection.

    Conclusions:

    • Interferon is an effective treatment for chronic viral hepatitis, particularly type C, but relapse is a concern.
    • The optimal duration of interferon treatment for chronic viral hepatitis requires further investigation.
    • Hepatitis Delta infection necessitates additional research into effective therapeutic strategies.